Biophytis presented its Phase 2-3 COVA study results in severe forms of
Covid-19 at the WCID in Paris
Biophytis / Key word(s): Miscellaneous
Biophytis presented its Phase 2-3 COVA study results in severe
forms of Covid-19 at the WCID in Paris
01-Jul-2024 / 07:00 CET/CEST
____________________________________________________________
Biophytis presented its Phase 2-3 COVA study results in severe
forms of Covid-19 at the WCID in Paris
Paris (France) and Cambridge (Massachusetts, USA), July 01st,
2024 - 07:00am CET - Biophytis SA (Euronext Growth Paris :
ALBPS), ("Biophytis" or the "Company"), a clinical-stage
biotechnology company specialized in the development of
therapeutics for age-related diseases, presented the roll-out
and results of its phase 2/3 COVA study in the treatment of
severe forms of Covid-19 at the 6th edition of the World Congress
on Infectious Diseases, held from June 24 to 26, 2024 in Paris,
France.
Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious
Diseases department at Pitié Salpetriere, presented the COVA
phase 2/3 clincial study results in a context where the number of
Covid cases rises again. Dr. Claudia Ferreira MD, PhD, Medical
Director at Biophytis, opened the conference with a keynote
presentation on the risk of infectious diseases and further
pandemic developments associated with the Paris Olympic games
including an increase of +52 % in emergency room (ER) visits due
to SARS-CoV-2 on the week of 10-17 June 2024 in France. She also
chaired several roundtables.
Valerie Pourcher detailed the results of the randomised,
placebo-controlled Phase 2/3 COVA study and the efficacy of oral
BIO101 (20-hydroxyecdysone) administered orally in adult patients
hospitalised for severe forms of COVID-19.
The results of this phase 2-3 study, evaluating BIO101 in the
treatment of severe hospitalised COVID-19 patients, are positive
and show, in addition to a very good safety profile, a
statistically significant reduction in the relative risk of early
respiratory failure or death of 43.8% and a 44.6% reduction in
the death rate over 90 days.
Stanislas Veillet, CEO of Biophytis, stated: " The Covid pandemic
is far from over: according to the World Health Organization,
134,797 new cases of Covid-19 and 1,691 deaths have been reported
worldwide in the last 28 days as of June 9 - a figure that is
underestimated due to under-reporting. Our COVA program, which
showed very positive resullts, positions BIO101
(20-hydroxyecdysone) as a leading drug candidate for severe
forms of Covid-19, particularly in elderly patients with
co-morbidities, that is independent of the SARS-COV2 strain."
The poster presented at the Congress, which details the
objectives, the design and the results of the study, can be
viewed by clicking on this link.
* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company
specializing in the development of drug candidates for
age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug
candidate, is a small molecule in development for muscular
(sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
respiratory (Covid-19 phase 2-3 completed) and metabolic diseases
(obesity, phase 2 to be started). The company is based in Paris,
France, and Cambridge, Massachusetts. The Company's ordinary
shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825). For more information, visit www.biophytis.com
Forward-looking statements
This press release contains forward-looking statements.
Forward-looking statements include all statements that are not
historical facts. In some cases, you can identify these
forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues,"
"may," "will," "should," "could," "seeks," "predicts,"
"intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such
forward-looking statements are based on assumptions that
Biophytis considers to be reasonable. However, there can be no
assurance that the statements contained in such forward-looking
statements will be verified, which are subject to various risks
and uncertainties. The forward- looking statements contained in
this press release are also subject to risks not yet known to
Biophytis or not currently considered material by Biophytis.
Accordingly, there are or will be important factors that could
cause actual outcomes or results to differ materially from those
indicated in these statements. Please also refer to the "Risk and
uncertainties the Company is to face» section from the Company's
2023 Financial Report available on BIOPHYTIS website
(www.biophytis.com) and as exposed in the "Risk Factors" section
of form 20-F as well as other forms filed with the SEC
(Securities and Exchange Commission, USA). We undertake no
obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as required by law.
Biophytis contacts
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
____________________________________________________________
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this
announcement.
____________________________________________________________
Language: English
Issuer: Biophytis
14 avenue de l´Opéra
75001 Paris
France
Internet: https://www.biophytis.com
ISIN: US09076G1040, FR0012816825
EQS News ID: 1936247
End of Announcement - EQS News Service
____________________________________________________________
1936247 01-Jul-2024 CET/CEST